PortugalTuberculosis profile
Population  2016 10 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.21 (0.21–0.22) 2 (2–2.1)
Mortality (HIV+TB only) 0.045 (0.029–0.064) 0.43 (0.28–0.62)
Incidence  (includes HIV+TB) 2.1 (1.8–2.4) 20 (17–23)
Incidence (HIV+TB only) 0.29 (0.24–0.34) 2.8 (2.4–3.3)
Incidence (MDR/RR-TB)** 0.028 (0.017–0.04) 0.27 (0.16–0.39)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.089 (0.075–0.1) 0.64 (0.54–0.74) 0.73 (0.62–0.84)
Males 0.099 (0.084–0.11) 1.2 (1–1.4) 1.3 (1.1–1.5)
Total 0.19 (0.16–0.22) 1.9 (1.6–2.2) 2.1 (1.8–2.4)
TB case notifications, 2016  
Total cases notified 1 836
Total new and relapse 1 794
          - % tested with rapid diagnostics at time of diagnosis 16%
          - % with known HIV status 66%
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 87%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.13 (0.11–0.15)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 168 14%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  19
(10–27)
Estimated % of TB cases with MDR/RR-TB 0.98% (0.51–1.7) 6.9% (2.8–14)  
% notified tested for rifampicin resistance 44% 52% 811
MDR/RR-TB cases tested for resistance to second-line drugs   5
Laboratory-confirmed cases MDR/RR-TB: 15, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 16, XDR-TB: 2
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 72% 2 114
Previously treated cases, excluding relapse, registered in 2015 56% 39
HIV-positive TB cases registered in 2015 51% 218
MDR/RR-TB cases started on second-line treatment in 2014 52% 25
XDR-TB cases started on second-line treatment in 2014 67% 3
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data